Tonix Pharmaceuticals Highlights Positive Data on TNX-801 Vaccine at World Vaccine Congress
Tonix Pharmaceuticals presents positive preclinical data on TNX-801 vaccine at World Vaccine Congress, demonstrating efficacy against mpox and rabbitpox. The vaccine aligns with WHO standards, offering potential for broad application in global health emergencies.
This news matters as Tonix Pharmaceuticals' TNX-801 vaccine candidate shows promising results in protecting against mpox and rabbitpox, aligning with global health emergency standards. The development of such vaccines is crucial for public health preparedness and response to infectious disease outbreaks.
